Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Platform Trial of Targeted Therapies for Treatment of Adult Subjects With Moderate to Severe Psoriasis

NCT07933536 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Platform Trial of Targeted Therapies for Treatment of Adult Subjects With Moderate to Severe Psoriasis
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 3, 2026
Completion date
December 31, 2028
Enrollment
105 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe psoriasis

Arms

As registered; 2 arms.

  • Risankizumab and ABBV-295 Combination Therapy ExperimentalABBV-295, Risankizumab

    Participants will receive risankizumab in combinations with ABBV-295 for up to 52 weeks.

  • Risankizumab and ABBV-295 Matching Placebo Active comparatorABBV-295 Placebo, Risankizumab

    Participants will receive risankizumab with ABBV-295 matching placebo for up to 52 weeks.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Percentage of Participants Achieving at least a 90% reduction from Baseline in Psoriasis Area and Severity Index (PASI 90) Week 28

    PASI is a measure of psoriatic disease severity taking into account the overall severity of erythema, induration and scaling, and the extent of affected area in each of four anatomical regions (head, trunk, upper extremities, and lower extremities). PASI scores range from 0 (no psoriasis) to 72 (severe disease over the entire body surface). Higher scores indicate worse disease severity. PASI 90 indicates at least 90% improvement from baseline.

  • Number of Participants with Adverse Events (AEs) Up to 72 Weeks

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Lead sponsor's other trials

AbbVie, most recent start first.

Similar trials

Same condition (Psoriasis) and phase, most recent start first.